Committed to harnessing the power and potential of genome editing to develop transformative medicines for patients suffering from serious diseases


Editas Medicine (NASDAQ: EDIT) is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.


Year Invested: 2013
Location: Cambridge, Mass.
Visit: www.editasmedicine.com

Recent News

May 15, 2017
Editas Medicine Announces First Quarter 2017 Results and Update

May 13, 2017
Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas

May 11, 2017
Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia

Read More News

Associated Team Members

Alexis Borisy
Partner